CLOs on the Move

Dentalcorp

www.dentalcorp.ca

 
dentalcorp is Canada`s largest network of dental practices, committed to advancing the overall well-being of Canadians by aiming to deliver the best clinical outcomes and unforgettable experiences. dentalcorp acquires leading dental practices, uniting them in a common goal: to be Canada`s most trusted healthcare network. Leveraging its industry-leading technology, know-how and scale, dentalcorp offers professionals the unique opportunity to retain their clinical autonomy while unlocking their potential for future growth. dentalcorp provides world-class resources to Partners including Talent & Recruitment, Human Resources, Training & Development, Legal & Compliance, Practice Optimization, Marketing, IT, Procurement, Finance, AP, and Payroll. We enable the ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.dentalcorp.ca
  • 181 Bay Street Suite 2600
    Toronto, ON CAN M5J 2T3
  • Phone: 416.558.8338

Executives

Name Title Contact Details
Julian Perez
 Chief Legal Officer Profile

Similar Companies

Bay Area Hospital

Bay Area Hospital is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Bay Area Hospital is based in Coos Bay, OR. You can find more information on Bay Area Hospital at www.bayareahospital.org

Addiction Recovery Resources (ARR)

Addiction Recovery Resources (ARR) is a Metairie, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthcare of Today

Healthcare of Today is a Burbank, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Highland Park Healthcare Inc

Highland Park Healthcare Inc is a Highland Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.